Onkológia 2/2023
Kam posunul trastuzumab deruxtecan liečbu HER2+ pozitívneho karcinómu prsníka?
HER2-positive breast cancer is one of the most aggressive types of breast tumors and, before discovery of trastuzumab, had the worst prognosis regardless of receptor status. By expanding portfolio of drugs based on blockade of HER2 receptor, treatment became chronic. Recently, trastuzumab deruxtecan has significantly improved survival parameters and changed recommendations for second- and higher-line treatment of metastatic breast cancer.
Keywords: HER2-positive breast cancer, treatment, trastuzumab deruxtecan
